Stroke is the Second Cause of Mortality Worldwide: ACTICOR-BIOTECH Expands ACTIMIS Stroke Study to the UNITED STATES — Shahin Gharakhanian MD Consulting LLC Leads Nationwide Project from Cambridge MA
April 3, 2020
Cambridge MA, 02.03.2020. Stroke is listed as the 2nd cause of mortality worldwide according to the World Health Organization. ACTICOR-BIOTECH [CEO: Dr Gilles AVENARD], a leading, fully-funded, PARIS-based, biotechnology company is assessing its novel agent ACT017 as an add on therapy to Standard of Care in AIS: Acute Ischemic Stroke. This year Acticor-Biotech has received the <French Tech> accreditation. Our organization, Shahin Gharakhanian MD Consulting LLC, was selected by Acticor-Biotech to optimally coordinate, direct and pilot the extension of this study named <ACTIMIS>, currently ongoing in the EU, to the United States. We are deploying a high performing Team, comprised of our selected partner Clinical Research Organization – PPD Biotech – as well as our own collaborators and field-based resources.
We are humbled by the confidence from this Sponsor in our LLC’s [est. 2011] expertise and capabilities. Together, with our US & EU Investigative Centers, we hope to impact treatment outcome in this important area of unmet medical need. For all information on ACTICOR-BIOTECH, please visit: https://acticor-biotech.com
ACT017 Reference: Artioscler Throm Vasc Biol 2019; 39: 956-964. DOI:10.1161/ATVBAHA.118